Texas
LATEST FROM BIOSPACE
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The U.S. Securities and Exchange Commission has launched an investigation into Texas-based Cassava Sciences.
Investors are falling in with these biotech companies, dropping dollars to fuel their work for the latest advancement in life sciences.
Houston-based money manager Alan Eisenman testified in the ongoing Elizabeth Holmes fraud trial that he sought “straight answers” about the company’s work for several years.
Vaxxinity set its initial public offering price at $13 per share, raising $76 million. The company was launched in April via consolidation of the vaccine development efforts of COVAXX and United Neuroscience.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
A new study was published this week and proposed a potential new biomarker for predetermining patient responsiveness to immune checkpoint blockade therapy.
Yet another busy week for clinical trial news. Here’s a look.
PRESS RELEASES